Research Topics
| M W FriedSummaryAffiliation: University of North Carolina Country: USA Publications
| Collaborators
|
Detail Information
Publications
Hemophilic siblings with chronic hepatitis C: Familial aggregation of spontaneous and treatment-related viral clearanceMichael W Fried
Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
Gastroenterology 131:757-64. 2006..Hemophilic siblings provide a unique population to explore the natural history of chronic hepatitis C...- HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis BMichael W Fried
University of North Carolina, Chapel Hill, NC 27599 7584, USA
Hepatology 47:428-34. 2008.... - Side effects of therapy of hepatitis C and their managementMichael W Fried
Division of Digestive Diseases, University of North Carolina, Chapel Hill, North Carolina 27599, USA
Hepatology 36:S237-44. 2002..Strategies to maximize adherence are being developed and, in the future, may include early identification of and therapy for depression and the selective use of hematopoietic growth factors to ameliorate hematologic abnormalities... - Treatment of chronic hepatitis C infection with peginterferons plus ribavirinMichael W Fried
University of North Carolina, Chapel Hill, North Carolina 27599 7080, USA
Semin Liver Dis 24:47-54. 2004..This article reviews the data from clinical trials of peginterferon alfa-2a and peginterferon alfa-2b... - Hepatitis C infection with normal liver chemistry testsMichael W Fried
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
Clin Gastroenterol Hepatol 6:503-5. 2008 - Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirinMichael W Fried
Division of Digestive Diseases, University of North Carolina, Chapel Hill 27599, USA
Hepatology 36:967-72. 2002..Adolescents treated with combination therapy had a significantly higher sustained response than adults did on the same regimen... - Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirinMichael W Fried
University of North Carolina, Chapel Hill, NC 27514, USA
Hepatology 48:1033-43. 2008.... - Advances in therapy for chronic hepatitis CM W Fried
Division of Digestive Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
Clin Liver Dis 5:1009-23. 2001.... - Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infectionMichael W Fried
University of North Carolina, Chapel Hill, NC 27599, USA
J Hepatol 55:69-75. 2011..The aim of the present study was to determine the relative importance of the kinetics of antiviral response compared to baseline host and virological factors for predicting SVR... - The role of triple therapy in HCV genotype 1-experienced patientsMichael W Fried
UNC Liver Center, University of North Carolina, Chapel Hill, NC 27514, USA
Liver Int 31:58-61. 2011..Regulatory approval of telaprevir and boceprevir is expected to begin in mid-late 2011... - Viral factors affecting the outcome of therapy for chronic hepatitis CMichael W Fried
Department of Medicine, Division of Digestive Diseases, University of North Carolina, Chapel Hill, NC, USA
Rev Gastroenterol Disord 4:S8-S13. 2004.... - Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infectionMichael W Fried
University of North Carolina, Chapel Hill 27599, USA
N Engl J Med 347:975-82. 2002.... - Management of newly diagnosed hepatitis C virus infectionMark W Russo
Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, USA
Cleve Clin J Med 70:S14-20. 2003..Careful and timely management of side effects, which are experienced by all patients, can improve adherence to antiviral therapy and further improve response rates... - R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirinPaul J Pockros
Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA 92037, USA
Hepatology 48:385-97. 2008..Dosing of R1626 was limited by neutropenia; a study of different dosages of R1626 in combination with peginterferon alfa-2a and ribavirin is underway... - Response-guided telaprevir combination treatment for hepatitis C virus infectionKenneth E Sherman
Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267 0595, USA
N Engl J Med 365:1014-24. 2011..We designed a noninferiority trial (noninferiority margin, -10.5%) to compare rates of sustained virologic response among patients receiving two treatment durations... - Psychiatric symptoms during interferon treatment for hepatitis C: experiences from a tertiary care hepatology centreD M Evon
Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Aliment Pharmacol Ther 27:1071-80. 2008..The findings from these lines of research may not be generalizable to patients treated under standard of care in a tertiary care setting... - Internal biliary stenting in orthotopic liver transplantationM W Johnson
Department of Surgery, Section of Transplantation, University of North Carolina, Chapel Hill 27599 7210, USA
Liver Transpl 6:356-61. 2000..Major advantages to this method are that it: (1) is completely internal, (2) is biliary decompressive, (3) is radiopaque, (4) can be spontaneously passed, and (5) is easily accessible for EGD extraction... - Side effects of therapy for chronic hepatitis CMark W Russo
Division of Digestive Diseases, University of North Carolina at Chapel Hill, 27599, USA
Gastroenterology 124:1711-9. 2003 - Guidelines for stopping therapy in chronic hepatitis CMark W Russo
Division of Gastroenterology and Hepatology, University of North Carolina, CB#7080, Room 1111, Bioinformatics Building, Mason Farm Road, Chapel Hill, NC 27599, USA
Curr Gastroenterol Rep 6:17-21. 2004..Progress in defining early treatment stopping points has reduced adverse events in patients who are unlikely to respond to therapy... - Hepatitis C: current options for nonresponders to peginterferon and ribavirinEmmanuel Thomas
University of North Carolina Chapel Hill, UNC Liver Program, Division of Gastroenterology and Hepatology, CB 7584, 8015A Burnett Womack Building, Chapel Hill, NC 27599, USA
Curr Gastroenterol Rep 10:53-9. 2008..The decision for further medical management is based on clinical and laboratory parameters that have been shown to predict which patients will benefit most from another attempt at therapy... - Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis BY O Kweon
University of North Carolina, CB# 7080, Room 708, Burnett-Womack Building, Chapel Hill, NC 27599, USA
J Hepatol 35:749-55. 2001..Immunohistochemical techniques are sensitive for assessing fibrogenesis and will be useful in trials of antiviral and antifibrotic agents... - Delayed neuropsychologic dysfunction after liver transplantation for acute liver failure: a matched, case-controlled studyElizabeth W Jackson
Liver Diseases Program, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Liver Transpl 8:932-6. 2002..Further studies are required to expand on these initial observations with the potential to improve patient care and referral to appropriate rehabilitative services... - Social stigmatization and hepatitis C virus infectionSteven Zacks
Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina at Chapel Hill, NC, USA
J Clin Gastroenterol 40:220-4. 2006..Our aim was to assess stigmatization by evaluating the impact of hepatitis C virus (HCV) on social interactions, feelings of rejection, internalized shame, and financial insecurity, and behavior... - Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infectionThomas D Parsons
University of North Carolina, Chapel Hill, North Carolina 27599 7025, USA
AIDS 20:1591-5. 2006..This study examined the effects of HAART on neurocognitive functioning in persons with hepatitis C virus (HCV) and HIV co-infection... - Optimizing treatment regimens in hepatitis CJama M Darling
Division of Gastroenterology and Hepatology, University of North Carolina, CB 7584, 8014 Burnett Womack Building, Chapel Hill, NC 27599 7584, USA
Clin Liver Dis 10:835-50. 2006.... - Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C studyDonna M Evon
Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, North Carolina 27599, USA
Am J Gastroenterol 104:2949-58. 2009..The objectives of this study were to determine the association between patient characteristics and depression before and during treatment and to evaluate the relationship between depression and treatment outcomes... - High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbiditiesDonna M Evon
Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina 27599, USA
Dig Dis Sci 52:3251-8. 2007..When patients are deferred for PI/SA but later treated, they have significantly higher rates of not completing treatment and a trend toward lower SVR rates... - Early hepatic stellate cell activation is associated with advanced fibrosis after liver transplantation in recipients with hepatitis CMark W Russo
Division of Gastroenterology and Hepatology, Center for Gastrointestinal Biology and Disease and University of North Carolina at Chapel Hill, NC 27599 7080, USA
Liver Transpl 11:1235-41. 2005..004). In conclusion, hepatic stellate cell activation early after liver transplantation complements traditional testing for identifying liver transplant recipients with hepatitis C at greatest risk for developing advanced fibrosis... - Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis CRoy L Hawke
Clinical Assistant Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, CB 7360, Kerr Hall Rm 3310, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7360, USA
J Clin Pharmacol 50:434-49. 2010..1 g per day were safe and well tolerated. The nonlinear pharmacokinetics of silybin A and silybin B suggests low bioavailability associated with customary doses of silymarin may be overcome with doses above 700 mg... - Impact of donor age and year of transplant on graft survival in liver transplant recipients with chronic hepatitis CMark W Russo
Department of Medicine and the Center for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, NC, USA
Am J Transplant 4:1133-8. 2004..Older donor age is associated with lower short-term graft survival in recipients with hepatitis C, but not in recipients with cholestatic or alcoholic liver disease... - Liver transplantation for acute liver failure from drug induced liver injury in the United StatesMark W Russo
Division of Gastroenterology and Hepatology, Department of Medicine and Center for Gastrointestinal Biology and Diseases, University of North Carolina, Chapel Hill, NC 27599 7080, USA
Liver Transpl 10:1018-23. 2004..The increased frequency of African-American women undergoing liver transplantation for non-APAP drug induced liver injury warrants further study... - Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United StatesMark W Russo
Department of Medicine, University of North Carolina, Chapel Hill, NC 27599 7080, USA
Liver Transpl 10:340-6. 2004..68. Short-term patient and graft survival are similar between living donor and deceased donor liver transplant recipients with hepatitis C suggesting that recurrent hepatitis C does not seem to affect short-term outcomes... - Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis CDickens Theodore
University of North Carolina at Chapel Hill, North Carolina 27599, USA
Dig Dis Sci 48:140-5. 2003..Nelson-Aalen cumulative hazard estimates for the different race and dose combinations revealed that Caucasians who received daily interferon were most likely to have an initial response (logrank, P < 0.001)... - Barriers to accessing care in patients with chronic hepatitis C: the impact of depressionD M Evon
Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, NC 27599, USA
Aliment Pharmacol Ther 32:1163-73. 2010..Patients with hepatitis C viral (HCV) may perceive barriers to accessing speciality care for HCV, and these barriers may be related to depressive symptoms... - The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activitySarah J Schrieber
Division of Pharmacotherapy and Experimental Therapeutics, School of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599 7360, USA
Drug Metab Dispos 36:1909-16. 2008..Patients with cirrhosis had the highest plasma caspase-3/7 activity and also achieved the highest exposures for the major silymarin flavonolignans... - Hepatitis B and C and renal failureS L Zacks
Division of Digestive Diseases and Nutrition, University of North Carolina at Chapel Hill, North Carolina, USA
Infect Dis Clin North Am 15:877-99. 2001..Further studies are required to identify the mechanisms of infection of patients with end-stage renal disease and to define better treatment strategies for these patients before and after kidney transplantation... - Use of transjugular intrahepatic portosystemic shunt as a bridge to liver transplantation in a patient with severe hepatopulmonary syndromeH M Lasch
Division of Digestive Diseases and Nutrition, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
Liver Transpl 7:147-9. 2001..We report a case of severe HPS in which a transjugular intrahepatic portosystemic shunt was successfully used to improve oxygenation, thus allowing a successful elective OLT... - Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis CD Theodore
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Haemophilia 10:413-21. 2004..This requires close coordination of care between the hepatologist and the haematologist. Indications for liver biopsy should be the same in patients with haemophilia as in other populations... - Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extractZhiming Wen
School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
Drug Metab Dispos 36:65-72. 2008..These data suggest that, after oral administration, silymarin flavonolignans are quickly metabolized to their conjugates, primarily forming glucuronides, and the conjugates are primary components present in human plasma... - Metastatic leiomyosarcoma mimicking polycystic liver diseaseKimberly L Beavers
Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7080, USA
Liver Transpl 8:1192-4. 2002 - Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trialNicholas J Shaheen
Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, NC, USA
Hepatology 41:588-94. 2005..However, the total ulcer number and patient symptoms were not different between the groups... - Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trialPaul J Pockros
Division of Gastroenterology/Hepatology, Scripps Clinic, La Jolla, California 92037, USA
Am J Gastroenterol 99:1298-305. 2004..A significantly higher proportion of patients treated with the 180 microg dose of peginterferon alpha-2a had clinically significant histological improvement... - Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)Samuel S Lee
Faculty of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1
J Hepatol 37:500-6. 2002..We evaluated the prognostic value of baseline factors and early viral RNA among patients treated with peginterferon alfa-2a (40KD)... - High relapse rate seen at week 72 for patients treated with R1626 combination therapyPaul Pockros
Hepatology 48:1349-50. 2008 - Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirinNancy Reau
Center for Liver Diseases, University of Chicago Hospitals, Chicago, Illinois 60637, USA
Am J Gastroenterol 103:1981-8. 2008..The objective of this analysis was to elucidate baseline and on-treatment factors predictive of a considerable hemoglobin drop at week 4... - Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment responseJordan J Feld
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
Hepatology 46:1548-63. 2007..Collectively, these mechanisms may provide a molecular basis for the improved efficacy of combination therapy... - Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year studyRobert G Gish
California Pacific Medical Center, San Francisco, CA, USA
J Hepatol 43:60-6. 2005..Based on these data, 200 mg emtricitabine once daily was chosen as the optimal dose for future hepatitis B studies... - Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis BGeorge K K Lau
Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR, China
N Engl J Med 352:2682-95. 2005.... - Current therapy for hepatitis C: pegylated interferon and ribavirinJohn G McHutchison
Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27710, USA
Clin Liver Dis 7:149-61. 2003.... - Chronic hepatitis B: a critical appraisal of current approaches to therapyRobert P Perrillo
Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
Clin Gastroenterol Hepatol 4:233-48. 2006..Expert opinions may differ from those of practicing hepatologists and gastroenterologists. We aimed to explore this issue further after a critical review of the literature... - Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1Hari S Conjeevaram
Division of Gastroenterology, The University of Michigan, Ann Arbor, Michigan 48109 0362, USA
Gastroenterology 131:470-7. 2006..Compared with Caucasian Americans (CA), African Americans (AA) with chronic hepatitis C are less likely to respond to interferon-based antiviral therapy... - Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirinPeter Ferenci
Medical University of Vienna, Vienna, Austria
J Hepatol 43:425-33. 2005..Prediction of sustained virological response (SVR) during treatment would allow clinicians to identify patients most likely to benefit from therapy... - Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis CYing Huang
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
Gastroenterology 132:733-44. 2007..To understand IFN-alpha resistance in vivo, we examined the dynamic responses to both type I and type II IFNs, human IFN (hIFN)-alpha, -gamma, and consensus IFN, in the chimpanzee model... - Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirinGraham R Foster
The Royal London Hospital, London, UK
Scand J Gastroenterol 42:247-55. 2007..The purpose of this study was to model the probability of achieving a sustained virological response in individual patients, taking into consideration various predictive factors... - Assessing the validity of self-reported medication adherence in hepatitis C treatmentScott R Smith
The Center for Outcomes and Evidence, Agency for Healthcare Research and Quality, Rockville, MD 20850, USA
Ann Pharmacother 41:1116-23. 2007..To assess the validity of self-reported medication adherence provided by individuals in treatment for hepatitis C virus (HCV) infection with a regimen of peginterferon and ribavirin... - Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis CStefan Zeuzem
Klinik fur Innere Medizin II, Universitatskliniken des Saarlandes, 66421 Homburg Saar, Germany
J Hepatol 39:106-11. 2003..Sensitive molecular tests may permit earlier determination of sustained virologic response following the completion of therapy in end-of-treatment responders... - Certificate of added qualification for hepatology: vindication not vanityMichael W Fried
Gastroenterology 128:817. 2005 - Hepatitis C and alcohol: fundamental and translational research directionsTimothy R Morgan
Department of Medicine, Veterans Adminstration Medical Center, Long Beach, California, USA
Alcohol Clin Exp Res 27:726-31. 2003..This article summarizes the panel's deliberations and their recommendations for future research on alcohol and hepatitis C...